Stocks · News reference
Glioblastoma a common and aggressive primary brain cancer in adults. Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
SL Science Holding Limited announced its unaudited financial results for the six months ended June 30, 2026, reporting a 23% increase in net revenue and an expansion in gross margins.
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
U.S. futures rose, but NetApp fell 8.2% after earnings. Ultragenyx plunged 45% on a failed trial; HPE, Methode and others also traded lower premarket.
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ:SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of